Journal article
Hepatitis C: An update
J Holmes, A Thompson, S Bell
Australian Family Physician | Published : 2013
Abstract
Background Chronic hepatitis C (CHC) infection remains a significant health issue. Most patients are asymptomatic, but long term infection may cause liver failure, liver cancer, and death. Projections estimate that these complications will triple by 2020. Chronic hepatitis C infection is curable, and successful viral eradication reduces liver related complications. The landscape of CHC therapy is rapidly changing. Objective This article outlines the incidence, prevalence and natural history of CHC, and provides information that may assist the general practitioner in the assessment and management of CHC patients. Discussion Chronic hepatitis C infection is under-diagnosed and may lead to sign..
View full abstractGrants
Funding Acknowledgements
Alexander Thompson has received payment as an Advisory Board member for Abbvie, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Novartis and Roche; speaker for Gilead, Janssen, Merck Sharp & Dohme and Bristol-Myers Squibb; research grants from Gilead, Merck Sharp & Dohme and Roche. Sally Bell has received payment as a speaker for Merck Sharp & Dohme.